04:08 AM EDT, 09/21/2026 (MT Newswires) -- Syncona's (SYNC.L) portfolio company, Beacon Therapeutics, delivered positive topline results from its phase II/III Vista clinical trial of laru-zova as a treatment of the blinding condition X-linked retinitis pigmentosa. The study acheieved its US Food and Drug Administration-endorsed primary endpoint demonstrating statistically significant low luminesce visual acuity in patients, according to a Monday filing. Laru-zova also exhibited a favorable safety and tolerability profile, the London-listed life science investor said. Beacon will use the outcome to discuss the submission of a rolling biologics license application with global regulators in 2026.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.